The present specification discloses methods of detecting a pathogen of interest and components useful in carrying out these methods, including a pre-enrichment media, and enrichment media and a detection solution.

The present invention relates to vaccines comprising an effective amount of at least one antigen in a wa-ter-in-oil-in-water (WOW) emulsion and an additional adjuvant, and to the methods of preparation and uses thereof.

The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of heterologous proteins into eukaryotic cells.

The present invention relates to a novel bacteriophage ΦCJ26 (KCCM11464P) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by Salmonella by using the bacteriophage ΦCJ26 (KCCM11464P) or the composition.

The present invention relates to the use of phyllosphere-associated lactic acid bacteria that demonstrate inhibitory effects on the growth and maintenance of human pathogens, such as Salmonella enterica, on the surface of food products, particularly fresh fruits and vegetables. Particular strains of Enterococcus avium and Lactococcus lactis are described and detailed for their atypical pathogen-inhibiting phenotypes.

A molecular sensor that utilises dichroism can be used to identify the presence of specific molecules in a substance. The molecular sensor includes a sensor element comprising (i) a scaffold moiety and (ii) one or more receptor molecules for the target molecule attached to the scaffold moiety to form a scaffold/receptor complex, wherein the scaffold/receptor complex is modified to incorporate a chromophore and the modified scaffold/receptor complex has a high aspect ratio.

The present invention relates to vaccines comprising an effective amount of at least one antigen in a water-in-oil-in-water (WOW) emulsion and an additional adjuvant, and to the methods of preparation and uses thereof.

The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.

Perforin-2 (P2) is expressed by fibroblasts, microglia and macrophages and was found to be responsible for killing bacteria, for example, Mycobacteria smegmatis, M. avium, Salmonellae, MRSA (drug resistant Stapholococci), E. coli. Compounds identified by screening assays are selected based on the effects of these compounds on P2. Use of these compounds in the treatment of infectious diseases, in particular, bacteria and antibiotic-resistant bacteria is also provided.

The invention relates to a recombinant vaccine comprising a vector of avian adenovirus serotype 9 (FAdV-9) with an inserted exogenous sequence of nucleotides coding for an antigen of a disease of interest and replacing the non-essential region of the genome of the adenovirus; and a pharmaceutically acceptable vehicle, adjuvant and/or excipient; where the exogenous sequence of nucleotides is between the nucleotides 491-2782. The vector of this recombinant vaccine is stable when it is produced at an industrial level. Likewise, the recombinant vaccine, even when administered in combination with a vaccine against Marek's disease, produces a suitable immune response that is not affected by the interference caused by said vaccine against Marek's disease nor does the Marek's vaccine inactivate the vaccine according to the invention. This recombinant vaccine allows the barrier of the maternal antibodies to be broken or avoided, inducing a suitable immune response.

A portable system for real time detection of the presence of an infectious agent in a biological sample employs a reagent which detects the presence of a specific infectious agent in the sample, and emits a detectable signal when the reagent reacts with the sample and detects the presence of the infectious agent. A test cartridge has a reaction chamber for receiving the sample and the reagent. The reaction chamber has a predetermined internal geometry and at least one inner surface. Introducing the sample and the reagent into the test cartridge mixes the sample and the reagent. A testing unit receives the test cartridge, and includes a sensor for detecting an emitted detectable signal. The detection of the emitted detectable signal is indicative of the presence of the infectious agent in the sample.

The present invention relates to a novel porcine parvovirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Further the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.

The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of heterologous proteins into eukaryotic cells.

The present invention relates to the use of phyllosphere-associated lactic acid bacteria that demonstrate inhibitory effects on the growth and maintenance of human pathogens, such as Salmonella enterica, on the surface of food products, particularly fresh fruits and vegetables. Particular strains of Enterococcus avium and Lactococcus lactis are described and detailed for their atypical pathogen-inhibiting phenotypes.

The present invention relates to the simultaneous detection of Salmonella enterica serovars Typhi and Paratyphi A. More particularly, the invention relates to multiplex PCR amplification of specific gene regions of Pan-Salmonella, Salmonella enterica serovars Typhi and Paratyphi A, coupled with detection of the amplified products by electrophoresis or LFA.

The present invention relates to a method for the detection of Salmonella enterica (S. enterica) serovar Typhi. More particularly, the invention relates to assymetric isothermal helicase-dependent amplification of specific gene regions, coupled with detection of the amplified products by lateral flow assay.

The invention relates to a composition comprising a mixture of probiotics, fructanes of blue weber agave and nutrients with symbiotic action and biological interaction, live and metabolically active, which, with a single administration at the moment of the poultry's first ingestion at birth, in the incubator, acts on the intestines so as to maintain and/or restore the intestinal health and correct the common dysbiosis of the digestive tract in birds, generating antagonistic effects against the pathogens Salmonella Typhimurium and Clostridium Perfringens, individually or combined throughout the life thereof. It also increases the conversion factor between the food consumed by the bird throughout the raising thereof, up to the sacrifice thereof for human consumption and the weight thereof produced.

The invention relates to the identification of therapeutic agents and their use in improving immuno-therapies, improving nucleic acid vaccination (for instance DNA and RNA vaccination), and for improving transplantation. Furthermore, the inventive agents allow manipulation of the immune system, with therapeutic applications to autoimmunity and infection.

A recombinant vaccine comprising a serotype 9 fowl adenovirus vector (FAdV-9) having at least one exogenous nucleotide sequence inserted encoding at least one antigen of a disease of interest and replacing the adenovirus genome non-essential region, and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the at least one exogenous nucleotide sequence encoding at least one antigen of a disease of interest and replacing the adenovirus genome non-essential region is located between the 491 and 2782 nucleotides. The vector of this vaccine is stable for industrial scale production. Likewise, even when this vaccine is administered in combination with a vaccine against Marek's disease, both vaccines produce an adequate immune response which is not affected by interference between each other. In the same way, effectiveness of the recombinant vaccine is not affected by maternal antibodies, and is capable of inducing both an early and lasting protective response, even with only one application.

An article for detecting Salmonella microorganisms is provided. The article comprises a highly selective nutrient medium and a plurality of indicator systems. A method of using the article to detect Salmonella microorganisms is also provided.

本发明公开了种山羊免疫方法，具体步骤如下：在怀孕母羊分娩前20‑30天和10‑15天，分别对怀孕母羊皮下注射羔羊痢疾氢氧化铝菌苗次；每年3月初、9月中旬分别对羔羊皮下注射羔羊大肠杆菌疫苗各1次；每年3月对山羊皮下注射山羊传染性胸膜肺炎氢氧化铝菌苗次；每年3‑4月，对山羊皮下注射羊痘鸡胚化弱毒疫苗次；每年3月、9月分别对山羊口腔黏膜内注射口疮弱毒细胞冻干苗各次；每年3月、9月分别对山羊背部皮下注射羊链球菌氢氧化铝菌苗各次；每年3月、9月分别对山羊肌肉注射五联苗各次；每年9月中旬对山羊皮下注射第Ⅱ号炭疽菌苗次。本发明根据山羊生长环境的变化，使用不同的疫苗对山羊进行接种，降低了山羊发病率，提高养殖户的经济效益。

本发明公开了种能表达痢疾志贺氏菌1型病原菌的脂多糖合成酶基因簇的重组大肠杆菌，该菌含有痢疾志贺氏菌1型病原菌rfb基因簇中的rfbR(rhamnosyltransferase)，rfbQ(rhamnosyltransferase)和orf9(galactosyltransferase)，其基因型是W3110Δwbbl/p‑rfp+p‑O‑Ag。本发明还公开了所述菌在制备抗痢疾志贺氏菌1型病原菌的糖蛋白疫苗中的应用。此重组大肠杆菌可以生产痢疾志贺氏菌1型病原菌的脂多糖结构，以该菌为平台，可以进步低成本高效的生产抗志贺氏菌1型病原菌的糖蛋白疫苗，具有良好的工业开发和应用前景。

Disclosed are devices, systems, and methods for the rapid and accurate detection of analytes, including Salmonella.

Resumen de: US2017151319A1

The present invention refers to pharmaceutical products comprising immunogenic compositions for modulating the immune system, which comprise a therapeutically effective amount of a Immunological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS), in association with an antibiotic and one or more physiologically acceptable carriers, excipients, diluents or solvents. IN other embodiments, the present invention refers to methods to treat severe bacterial infections, sepsis and modulating the immune system.